Loading clinical trials...

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

A Randomized, Double-blind, Parallel Group, Placebo Controlled, 6-week Study of the Effect of GW685698X Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Children 2 to 11 Years of Age With Perennial Allergic Rhinitis (PAR).

NCT00116883•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.

Eligibility

Age

2 - 11 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis and history of perennial allergic rhinitis.
•Must be willing to stay overnight in the clinic at the beginning and end of the study for the collection of urine and blood samples over 24 hours.
•Must comply with all study procedures and be literate.

Exclusion Criteria

•Significant concurrent medical conditions.
•Certain medications such as corticosteroids and allergy medications.

Locations (12)

GSK Investigational Site

Hot Springs, Arkansas, United States

GSK Investigational Site

Little Rock, Arkansas, United States

GSK Investigational Site

Long Beach, California, United States

GSK Investigational Site

Jacksonville, Florida, United States

GSK Investigational Site

West Palm Beach, Florida, United States

GSK Investigational Site

Lafayette, Louisiana, United States

GSK Investigational Site

Rolla, Missouri, United States

GSK Investigational Site

Medford, Oregon, United States

GSK Investigational Site

Orangeburg, South Carolina, United States

GSK Investigational Site

Spartanburg, South Carolina, United States

Key Dates

Start Date

February 1, 2005

Primary Completion Date

July 1, 2005

Completion Date

July 1, 2005

Last Updated

September 15, 2016

Enrollment

ACTUAL participants

Conditions

Rhinitis, Allergic, Perennial

Interventions

GW685698X aqueous nasal spray

DRUG

A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

NCT00779545

Rhinitis, Allergic, Perennial

View study

COMPLETEDPHASE3

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

NCT00406783

Rhinitis, Allergic, SeasonalRhinitis, Allergic, Perennial

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 15, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

Inclusion Criteria

Exclusion Criteria

A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis

Single Dosing Clinical Trial of HL151

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)